Get the Stockscreener App
1.105
1.34%
-0.015
After Hours:
1.1281
0.0231
+2.09%
X4 Pharmaceuticals Inc stock is currently priced at $1.105, with a 24-hour trading volume of 3.54M.
It has seen a -1.34% decreased in the last 24 hours and a -21.63% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.14 pivot point. If it approaches the $1.07 support level, significant changes may occur.
Previous Close:
$1.12
Open:
$1.13
24h Volume:
3.54M
Market Cap:
$185.57M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-1.0625
EPS:
-1.04
Net Cash Flow:
$-96.57M
1W Performance:
-14.34%
1M Performance:
-21.63%
6M Performance:
+47.06%
1Y Performance:
-29.62%
1D Range:
$1.07
$1.14
52W Range:
$0.5723
$2.575
X4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
955 Massachusetts Avenue, 4th Floor, Cambridge, MA
X4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
GlobeNewswire Inc.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
GlobeNewswire Inc.
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
X4 Pharmaceuticals Inc Stock (XFOR) Financials Data
X4 Pharmaceuticals Inc (XFOR) Net Income 2024
XFOR net income (TTM) was -$101.17 million for the quarter ending December 31, 2023, a -7.78% decrease year-over-year.
X4 Pharmaceuticals Inc (XFOR) Cash Flow 2024
XFOR recorded a free cash flow (TTM) of -$96.57 million for the quarter ending December 31, 2023, a -25.09% decrease year-over-year.
X4 Pharmaceuticals Inc (XFOR) Earnings per Share 2024
XFOR earnings per share (TTM) was -$0.59 for the quarter ending December 31, 2023, a +68.45% growth year-over-year.
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
3.18%
Cap:
|
Volume (24h):